Chimeric antigen receptor therapy for chronic lymphocytic leukemia: what are the challenges? Review uri icon

Overview

abstract

  • Chimeric antigen receptor (CAR)-modified T cells targeting CD19 expressed by normal and malignant B cells is a unique therapy for patients with chronic lymphocytic leukemia (CLL); recent results highlight the potential of this therapy for patients with relapsed CLL. Because adoptive transfer of CAR-modified T cells is a novel approach, there are issues for the medical oncologist to consider when evaluating current and future clinical trials for CLL patients. This article reviews the impact of CAR design, T-cell production, T-cell dose, conditioning regimens, and tumor burden at the time of CAR-modified T-cell infusion on the efficacy of this therapy.

publication date

  • April 1, 2013

Research

keywords

  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Receptors, Antigen

Identity

PubMed Central ID

  • PMC3615434

Scopus Document Identifier

  • 84875778203

Digital Object Identifier (DOI)

  • 10.1016/j.hoc.2012.12.004

PubMed ID

  • 23561477

Additional Document Info

volume

  • 27

issue

  • 2